Skip to main navigation
Skip to search
Skip to main content
Sort by
Keyphrases
Vascular Endothelial Growth Factor
100%
Bevacizumab
100%
Antiangiogenic Therapy
100%
Advanced Colorectal Cancer
100%
Surrogate Biomarkers
100%
Colorectal Cancer
50%
Clinical Practice
25%
Dose Escalation
25%
Disease Progression
25%
Cancer Cells
25%
Mechanism of Action
25%
Tumor Endothelial Cells
25%
Phase I Trial
25%
Radiosensitivity
25%
Phase II Study
25%
Specific Antibodies
25%
Radiosensitization
25%
Randomized Phase III Trial
25%
Tumor Vasculature
25%
Tumor Oxygenation
25%
Targeted Therapy
25%
Conventional Chemotherapy
25%
Metastatic Colorectal Cancer (mCRC)
25%
Antivascular Therapy
25%
Antiangiogenic Agents
25%
Tumor Blood Vessels
25%
Drug Penetration
25%
Radiochemotherapy
25%
Locally Advanced Rectal Cancer
25%
Anti-vascular Endothelial Growth Factor (anti-VEGF)
25%
Treatment Line
25%
Medicine and Dentistry
Vasculotropin
100%
Colorectal Carcinoma
100%
Biological Marker
100%
Antiangiogenic Therapy
100%
Bevacizumab
80%
Neoplasm
40%
Rectum Cancer
40%
Cancer Cell
20%
Endothelial Cell
20%
Disease Exacerbation
20%
Targeted Therapy
20%
Chemoradiotherapy
20%
Vascular Tissue Neoplasm
20%
Radiosensitivity
20%
Phase I Trials
20%
Radiosensitizer
20%
Tumor Vascularization
20%
Angiogenesis Inhibitor
20%
Metastatic Colorectal Cancer
20%
Drug Penetration
20%
Phase III Trials
20%
Pharmacology, Toxicology and Pharmaceutical Science
Vasculotropin
100%
Colorectal Carcinoma
100%
Biological Marker
100%
Antiangiogenic Therapy
100%
Bevacizumab
80%
Neoplasm
40%
Rectum Cancer
40%
Malignant Neoplasm
20%
Chemotherapy
20%
Disease Exacerbation
20%
Phase I Trials
20%
Radiosensitizing Agent
20%
Tumor Vascularization
20%
Vascular Tumor
20%
Angiogenesis Inhibitor
20%
Metastatic Colorectal Cancer
20%
Phase III Trials
20%
Immunology and Microbiology
Vasculotropin
100%
Colorectal Carcinoma
100%
Bevacizumab
80%
Cancer Cell
20%
Radioresistance
20%
Blood Vessel
20%
Tumor Vascularization
20%
Angiogenesis Inhibitor
20%
Oxygenation
20%
Drug Penetration
20%